Update shared on07 Aug 2025
Fair value Increased 18%Despite a sharp downgrade in revenue growth forecasts, Lexicon Pharmaceuticals’ consensus analyst price target has increased notably, supported by a lower future P/E ratio and now stands at $3.05.
What's in the News
- Post-hoc analysis of clinical data showed sotagliflozin reduced hypoglycemia events without increased risk across kidney function subgroups in type 1 diabetes patients using optimized insulin therapy.
- Shareholders approved an amendment allowing a reverse stock split of common shares at a ratio between 1-for-10 and 1-for-50, at the board's discretion, before the 2026 annual meeting.
- Details of the Phase 3 SONATA-HCM study evaluating sotagliflozin in both obstructive and non-obstructive hypertrophic cardiomyopathy were presented; enrollment is underway across 20 countries, aiming for 500 patients, with potential sNDA support based on results.
- Q2 2025 results are expected to be reported on July 31, 2025.
Valuation Changes
Summary of Valuation Changes for Lexicon Pharmaceuticals
- The Consensus Analyst Price Target has significantly risen from $2.59 to $3.05.
- The Consensus Revenue Growth forecasts for Lexicon Pharmaceuticals has significantly fallen from 10.7% per annum to -2.9% per annum.
- The Future P/E for Lexicon Pharmaceuticals has significantly fallen from 211.21x to 181.30x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.